Search Results
Your search for The ASCO Post matches 17639 pages
Showing 16001 - 16050Cancer Researchers Receive the Nobel Prize in Chemistry 2015
The Nobel Prize in Chemistry 2015 recipients were recently announced. They are Tomas Lindahl, PhD, Paul Modrich, PhD, and Aziz Sancar, PhD, for having mapped, at a molecular level, how cells repair damaged DNA and safeguard the genetic information. Their work has provided fundamental knowledge of...
California Agency Invests $20 Million in Clinical Trial for Glioblastoma Vaccine
California’s Stem Cell Agency (CIRM) has awarded $19.9 million to ImmunoCellular Therapeutics to carry out a phase III clinical trial in patients with newly diagnosed glioblastoma using an immunotherapeutic vaccine. “This kind of deadly disease is precisely why we created CIRM 2.0, our new...
Alexander Eggermont, MD, PhD, to Lead Gustave Roussy for 5 More Years
Alexander Eggermont, MD, PhD, the General Director of Gustave Roussy since 2010, has had his appointment at the Head of the Institute renewed by the French Minister of Health for 5 years, with this term beginning October 1, 2015. Success of 2010–2015 Period The 2010–2015 period was primarily one in ...
Bevacizumab in Ovarian Cancer: Results of ICON7
Based on preclinical (in vitro and in vivo) data, there is a strong biologic rationale for the addition of an antiangiogenic drug strategy in the treatment of epithelial ovarian cancer.1 Single-agent trials have confirmed both the biologic and clinical activity of bevacizumab (Avastin) in the...
Addition of Bevacizumab to Standard Chemotherapy Improves Overall Survival Only in High-Risk Ovarian Cancer
Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Amit M. Oza, MD, and colleagues indicate no significant improvement with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer.1 However, an overall...
Anti-EGFR Therapy in Squamous Cell Lung Carcinoma: Swimming With or Against the Tide?
Lung cancer is the most common, lethal, and costly cancer worldwide, accounting for at least 1.8 million new cases per year (12.9% of the total).1 Over the past decade, there has been a major shift in the treatment of non–small cell lung cancer (NSCLC), especially in adenocarcinoma, accompanied by...
FDA Approves Expanded Indication for Medical Device to Treat Newly Diagnosed Glioblastoma Multiforme
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for the Optune tumor-treating fields device to treat patients with newly diagnosed glioblastoma multiforme. It is given along with the chemotherapy drug temozolomide following standard treatments that include surgery,...
FDA Grants Accelerated Approval to Pembrolizumab for Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for pembrolizumab (Keytruda) to treat patients with metastatic non–small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express programmed cell death-ligand 1 (PD-L1)....
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to elicit ...
FDA Approves Use of Nivolumab in Metastatic Nonsquamous Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) to treat patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy. Nivolumab is a monoclonal antibody that that blocks the PD-1/PD-L1...
Three Young Investigators Named Winners of 2015 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSKCC) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger for their efforts in advancing cancer research. The winners are Bradley E. Bernstein, MD,...
CancerCare® Welcomes Christine Verini, RPh, as Chief Business Development Officer
CancerCare®, a national nonprofit organization providing free, professional support services to anyone affected by cancer, is pleased to welcome Chief Business Development Officer Christine Verini, RPh. In her role, Ms. Verini will serve as a key member of CancerCare’s Executive Leadership Team,...
Children’s Healthcare, Emory Name Douglas Graham, MD, PhD, Director of Aflac Cancer and Blood Disorders Center
Children’s Healthcare of Atlanta and Emory University has announced that William G. Woods, MD, has stepped down as Director of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Chief of Hematology/Oncology/BMT in the Department of Pediatrics at Emory University....
UCSF Receives $5 Million NCI Grant to Integrate Data From Cancer Research Models
The University of California, San Francisco (UCSF) has received a National Cancer Institute grant of $5 million over the next 5 years to lead a massive effort to integrate the data from all experimental models across all types of cancer. The Web-based repository is an important step in moving the...
UPCI Wins $10.9 Million Grant Renewal for Head and Neck Cancer Research
University of Pittsburgh Cancer Institute (UPCI) researchers have received renewal of their head and neck cancer research through the National Cancer Institute’s competitive Specialized Program of Research Excellence (SPORE) program. The 5-year, $10.9 million grant includes a new project to study...
UNC-Chapel Hill Researchers Awarded $11.3 Million for Four Cancer Nanotechnology Projects
University of North Carolina (UNC) at Chapel Hill researchers received an $11.3 million, 5-year grant to conduct multiple studies exploring the use of tiny nanoparticles to create cancer vaccines and improve cancer drug delivery and responses. The grant is the third in a series of awards that the...
Many Patients Do Not Accurately Recall Important Colonoscopy Details as Time Lapses
As time lapses, many patients who have undergone a colonoscopy become less and less likely to recall when and where they last had the procedure performed, who the doctor was who performed it, whether polyps were found, and, if so, the number and size of those polyps, according to new study results...
Conquer Cancer Foundation Grants and Awards: Funding Opportunities Now Available
The Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (CCF) is fueling cancer research and pursuing dramatic advances in the diagnosis, prevention, treatment, and cure of all types of cancer. CCF’s Grants and Awards program supports clinical and translational cancer...
Philip A. Salem, MD, Awarded the FOEDUS Supreme Medal of Excellence
FOEDUS, the Italian Foundation of Culture and Science, awarded the Supreme Medal of Excellence to oncologist Philip A. Salem, MD, Director Emeritus of Cancer Research at Baylor St. Luke’s Medical Center in Houston and President of the Salem Oncology Center at the Texas Medical Center. The...
Important Research in the Palliative Care of Patients With Cancer
The emphasis at this year’s Palliative Care in Oncology Symposium, held earlier this month in Boston, was on patient-centered care throughout the cancer continuum. The meeting attracted more than 650 attendees and included six general sessions featuring best practices in communication,...
Expert Point of View: Michael F. Greene, MD, and Dan L. Longo, MD
In an accompanying editorial in The New England Journal of Medicine, Michael F. Greene, MD, Chief of Obstetrics at Massachusetts General Hospital, and Dan L. Longo, MD, Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, mentioned the low odds for both oncologists and...
Ovarian Suppression During Chemotherapy Preserves Fertility in Young Women With Breast Cancer
Several studies have addressed the risks and benefits of ovarian suppression during chemotherapy for breast cancer in women of childbearing age. A new meta-analysis of randomized trials found that it prevented premature ovarian failure and was associated with a higher number of pregnancies post...
FDA Approves First Oncolytic Viral Therapy in the United States
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma...
ASH Honors Aaron J. Marcus, MD, Posthumously With Award for Lifetime Achievement in Hematology
The American Society of Hematology (ASH) will recognize the late Aaron J. Marcus, MD, of Weill Cornell Medical College and the Veterans Affairs New York Harbor Healthcare System with the 2015 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Marcus, who passed away in May 2015,...
National Academy of Medicine Elects New Members
The National Academy of Medicine (NAM), formerly the Institute of Medicine, announced the election of 70 regular members and 10 international members during its Annual Meeting October 19. Election to the Academy is considered one of the highest honors in the fields of health and medicine and...
ASCO-Endorsed ASTRO Guidelines: Searching for Consensus on Radiotherapy for Endometrial Cancer
Endometrial cancer is the most common gynecologic cancer, but there has been little consensus about the appropriate indications for adjuvant therapy. One reason for the lack of consensus is the absence of randomized studies in endometrial cancer that report an overall survival benefit. This may be...
ASCO Endorses ASTRO Guideline on Postoperative Radiation Therapy for Endometrial Cancer
As reported in the Journal of Clinical Oncology by Larissa A. Meyer, MD, MPH, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) guideline on postoperative radiation therapy for endometrial cancer.1 The ASCO clinical practice guideline...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Frances Giles, MB, MD, FRCPI, FRCPath, Appointed Chief of Hematology/Oncology at Northwestern
Francis Giles, MB, MD, FRCPI, FRCPath, has been appointed Chief of the Division of Hematology/Oncology in the Department of Medicine at Northwestern. In his new role, he will continue to advance the division’s clinical, research, and academic pursuits. Dr. Giles joined the faculty of the Division...
NCI Names Thomas Kensler, PhD, Outstanding Investigator
Thomas Kensler, PhD, Professor of Pharmacology and Chemical Biology and Co-Leader for the Cancer Epidemiology and Prevention Program at the University of Pittsburgh Cancer Institute (UPCI), was awarded a $6.3 million Outstanding Investigator Award from the National Cancer Institute (NCI). This new...
A Cancer Diagnosis Can Lead to Significant Loss of Working Hours, Income
A new analysis indicates that when American adults are diagnosed with cancer, they experience significant decreases in the probability of working, in the number of hours they work, and correspondingly, in their incomes. Such negative impacts of a cancer diagnosis are particularly pronounced among...
Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear here with expert commentary. In the October 25 issue of The ASCO Post, part 1 of a...
2015 Oncology Meetings
NOVEMBER Best of ASTRONovember 13-14 • San Diego, California For more information: www.astro.org/Meetings-and-Events/2015-Best-of-ASTRO/Index.aspx 2015 Oncologic Emergency Medicine Conference November 13-14 • Houston, Texas For more information:...
NCI Division of Cancer Control and Population Sciences Names Kathy J. Helzlsouer, MD, MHS, Associate Director
Kathy J. Helzlsouer, MD, MHS, has been named Associate Director and Chief Medical Officer in NCI’s Division of Cancer Control and Population Sciences. She will direct the Epidemiology and Genomics Research Program, which includes the Office of the Associate Director, Clinical and Translational...
A Chemist Exposes Dangerous Chemicals
Bookmark Title: Pick Your Poison: How Our Mad Dash to Chemical Utopia Is Making Lab Rats of Us All Author: Monona Rossol Publisher: John Wiley & Sons Publication date: October 2015 Price: E-book, 210 pages Monona Rossol is a chemist and “industrial hygienist” who is a frequent contributor to...
A Pandemic’s Story of Tragedy and Success
Bookmark Title: AIDS Between Science and Politics Author: Peter Piot Publisher: Columbia University Press Publication date: May 2015 Price: $29.95; hardcover, 216 pages AIDS is a global phenomenon that recognizes neither national boundaries nor social strata. The AIDS pandemic was one of the...
Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the company’s investigational antibody-drug conjugate inotuzumab ozogamicin for acute lymphoblastic leukemia (ALL). The FDA’s decision was based on the results of the phase III ...
ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality
ASCO recently called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve “site neutrality” in...
Cancer on the Global Stage: Incidence and Cancer‑Related Mortality in Algeria
The ASCO Post is pleased to continue this special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Algeria. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For the ...
LUNGevity Foundation and Celgene Collaborate to Create Resource for Lung Cancer Caregivers
The LUNGevity Foundation and the biopharmaceutical company Celgene have joined forces to launch a new resource for caregivers of people diagnosed with lung cancer. The program, “Your Journey Together,” is a support tool focusing on the specific needs of this group and includes a series of videos,...
Peter A. Kanetsky, PhD, MPH, Named Next President of ASPO
Peter A. Kanetsky, PhD, MPH, Chair and Program Leader of Cancer Epidemiology at the Moffitt Cancer Center, has been elected as the new president for the American Society of Preventive Oncology (ASPO). He will serve as President-Elect before taking the post in March 2017. ASPO is a multidisciplinary ...
Martine Extermann, MD, PhD, Recognized for Her Work in Geriatric Oncology at Assembly in Basel, Switzerland
Martine Extermann, MD, PhD, senior member of Moffitt’s Senior Adult Oncology Program, has been honored with the Geriatric Oncology Lifetime Achievement Award, originally known as the “Preis geriatrische Onkologie für das Lebenswerk 2015,” at this year’s German, Austrian, and Swiss Congress of the...
Telotristat Etiprate Added to Standard Therapy for Carcinoid Syndrome Shows Clinical Benefit in Patients With Metastatic Neuroendocrine Tumors
The investigational drug telotristat etiprate was shown to have clinical benefit when added to somatostatin analog therapy for carcinoid syndrome not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, in patients with metastatic neuroendocrine tumors....
Geriatric Oncology in Europe: A Commitment to Improving Cancer Care for Older Patients
In Europe, the field of geriatric oncology has a long history of development, and its organization and implementation continue to improve every day. This would not have happened without the strong commitment of national authorities to health policies, a critical success factor. Four Missions In...
Lewis Cantley, PhD, Receives 2015 AACI Distinguished Scientist Award
The Association of American Cancer Institutes (AACI) presented the AACI Distinguished Scientist Award to Lewis Cantley, PhD, on October 26, during the 2015 AACI/Cancer Center Administrators Forum Annual Meeting, in Washington, DC. A cell biologist and biochemist who serves as The Margaret and...
Why Melanoma Rates Are Increasing in Adolescents and Young Adults, Especially Among Females
The incidence of melanoma among children, adolescents, and young adults has reached epidemic proportions, increasing more than 250% over the past 4 decades, with young females at highest risk for the deadly cancer, according to a study1 by researchers at Roswell Park Cancer Institute in Buffalo,...
UCLA and VA Launch Program to Enhance Cancer Care for Veterans
A new collaboration between the University of California, Los Angeles (UCLA) and the Veterans Affairs (VA) Greater Los Angeles Healthcare System will provide access to the latest therapeutic cancer clinical trials and state-of-the-art care for men and women who have served in the armed forces. The...
Survival and Bevacizumab in Early Breast Cancer: Time to Reconsider?
In metastatic HER2-negative breast cancer, several trials have shown that the addition of the anti–vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin) to different chemotherapy regimens significantly improved response rates and progression-free survival by various...
ASH Elects New Leadership to Its Executive Committee
The American Society of Hematology (ASH) has announced the election of three new members to its Executive Committee, the governing body of the organization, for terms beginning after the 2015 ASH Annual Meeting, taking place December 5–8 in Orlando. Alexis A. Thompson, MD, MPH, will serve a 1-year...
ASCO Recommendations for Use of White Blood Cell Growth Factors: What Remains the Same and What Has Been Modified
Neutropenic complications remain the main dose-limiting toxicity of cancer chemotherapy treatment and are associated with considerable morbidity, mortality, and costs.1 Although patients who have experienced a prior neutropenic event are at increased risk of subsequent events, several studies have...
